A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoACP3 in Patients With Prostate Cancer
← catalyst calendarSponsored by Philogen S.p.A. (industry) · PHIL.MI — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Diagnostic
Enrollment
20actual
Sites
3
Country
Italy
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-08 | actual | When the study began enrolling |
| Primary completion | 2025-10-03 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-10-03 | actual | The whole study's end, after follow-up |
| First posted | 2025-02-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Prostate Cancer
- Prostate Cancer Metastatic Disease
- PSA Level Greater Than 0.2
Intervention
- Drug: [68Ga]Ga-OncoACP3
Primary outcomes
what the primary-completion date above is the date OFCohort A: Dosimetry - Effective dose equivalent (mSv)
measured Assessed on day 1
Cohort A: Dosimetry - Effective dose absorbed doses (mGy)
measured Assessed on day 1
All patients: Safety (AEs and SAEs)
measured Throughout study, until a maximum of 7 days after the administration of the study drug.
Permalink · PHIL.MI's whole pipeline · Catalyst calendar · Every registered study · What changed